Ars Technica
2 months agoMedicine
$158,000 ALS drug pulled from market after failing in large clinical trial
The drug Relyvrio, approved for ALS treatment, did not show benefits in a clinical trial and is being pulled from the market.
The FDA approved Relyvrio despite shaky data, and the drug's failure highlights the need for more effective ALS treatments. [ more ]